Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 2/20 | 0.47 |
| ▸ | GRN | P28799 | 2/20 | 0.47 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LIPE | Q05469 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1968361 | 0.78 | ALDH1A1 (0.47) | CYP1A2CYP2C9CYP2C19POLBALDH1A1 | |
| SCHEMBL2255952 | 0.77 | PDE4B (0.56) | CTSAGRNSORT1OPRM1OPRD1 | |
| SCHEMBL4955898 | 0.74 | ALDH1A1 (0.61) | CYP2C9CYP2C19POLBALDH1A1HPGD | |
| SCHEMBL13224737 | 0.73 | SMN1; SMN2 (0.56) | CYP1A2CYP2C9CYP2C19L3MBTL1ALDH1A1 | |
| SCHEMBL7637674 | 0.71 | NPC1 (0.63) | CTSAGRNSORT1MCHR1ALDH1A1 | |
| SCHEMBL23149723 | 0.70 | GRN (0.51) | CTSAGRNSORT1OPRM1OPRD1 | |
| SCHEMBL4959888 | 0.70 | ALDH1A1 (0.56) | POLBALDH1A1HPGDGAANPC1 | |
| SCHEMBL1968562 | 0.70 | MAPK1 (0.52) | CYP1A2POLBALDH1A1HPGDGAA | |
| SCHEMBL1969591 | 0.70 | ALDH1A1 (0.46) | POLBALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL6120802 | 0.69 | OPRM1 (0.67) | CTSAGRNSORT1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312291-A1 | Heterocyclic Gaba-b Modulators | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | claimed |
| EP-1966176-A1 | HETEROCYCLIC GABA-B MODULATORS | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | claimed |
| WO-2007073296-A1 | HETEROCYCLIC GABA-B MODULATORS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | claimed |
| US-20080312291-A1 | Heterocyclic Gaba-b Modulators | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080312291-A1 | Heterocyclic Gaba-b Modulators | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080312291-A1 | Heterocyclic Gaba-b Modulators | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| EP-1966176-A1 | HETEROCYCLIC GABA-B MODULATORS | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007073296-A1 | HETEROCYCLIC GABA-B MODULATORS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312291-A1 | Heterocyclic Gaba-b Modulators | GABBR1, GABBR2, GABRB1 | CTSA 3124/4885GRN 2588/4885SORT1 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.